Navigation Links
Popular Heartburn Meds May Boost Fracture Risk
Date:5/9/2011

By Maureen Salamon
HealthDay Reporter

MONDAY, May 9 (HealthDay News) -- Reinforcing U.S. health officials' concerns, new Korean research suggests that long-term use of popular heartburn drugs such as Prilosec, Prevacid and Nexium is linked to an increased risk of fractures.

Scientists conducting a meta-analysis of 11 studies published between 1997 and 2011 found that proton pump inhibitors (PPIs), which reduce stomach acid production, were associated with a 29 percent increased risk of fracture. This included a 31 percent higher risk of hip fractures and a 54 percent heightened risk of vertebral fractures.

Another class of heartburn drugs known as H2-receptor antagonists or H2 blockers -- which include brand names such as Zantac and Pepcid -- were not significantly linked to fracture risk, according to the study authors. H2 blockers, however, are less powerful than PPIs at suppressing acid production, blocking only about 70 percent rather than the estimated 98 percent that can be blocked by PPIs.

"It is difficult to say uniformly what the absolute risk is because fracture risk shows many differences according to age, sex, race and ethnicity," said study lead author Dr. Chun-Sick Eom, a clinical instructor in the Department of Family Medicine at Hallym University Hospital in Chuncheon, Korea.

"Clinicians should carefully consider their decision to prescribe PPIs for patients at elevated risk for fracture, especially women older than 65 years of age," he added. "We recommend that drug doses be chosen thoughtfully with consideration of what is necessary to achieve desired therapeutic goals."

In addition, a subset of high-quality studies -- and studies adjusting for at least five variables that could also influence fracture risk -- did show an increase in fractures in people taking H2 blockers. For this reason, the study authors also recommended further study on that topic.

The study is published
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Is a Tummy Tuck Right for Me? Alabama Plastic Surgeon Dr. David Durst Offers Tips as the Popularity of Surgical Cosmetic Enhancement Continues to Rise
2. Americans Remain Split on Stalled Health Care Legislation, but Some Provisions Popular Among Majorities of Democrats, Independents and Republicans
3. Popular Diet Plans Can Unclog Arteries
4. Popular nanoparticle causes toxicity in fish, study shows
5. Personalized Live on-Demand Yoga Avatar Gains Popularity Amongst Users, Across all age Groups
6. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
7. "How Stupid Do They Think We Are?" --- Band Releases New Anthem in Support of Popular Citizens' Resistance
8. Future Apps Releases Major Update to its Popular iPhone Text to Speech App Speak it
9. Electronic Cigarettes Continue to Experience Popularity Growth
10. Passover paradox: The amazing popularity of kosher foods
11. Quantity, Not Quality, of Online Posts Builds Popularity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Popular Heartburn Meds May Boost Fracture Risk
(Date:7/30/2014)... 2014 According to the market ... Market by Technology (ICS, MES, ERP, ITS), Field ... FGOL), Application (Process, Discrete) - Global Forecast & ... the Mexican market is expected to reach $6.99 ... , Browse 70 market data Tables and 96 ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The North ... 1781.02 million by 2019. North America is expected to ... actuation market at a CAGR of 5.60%. , ... opportunities and challenges which will assume prominence in the ... the past, yet the sector has regained quickly, and ...
(Date:7/30/2014)... Vedic Studies (WAVES) conference is coming to Fairfield, Iowa,s ... through Sunday, August 3. To watch the main plenary ... first time such a large and diverse group of ... explore the relevance of ancient Vedic knowledge in today,s ... of consciousness, and reflections on the various Vedic texts. ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Medical costs for ... are more than $32 billion each year, according to ... and Prevention. The yearly financial toll of COPD ... reach an estimated $49 billion by 2020. "For ... COPD, which provide state public health practitioners with estimates ...
(Date:7/30/2014)... This news release is available in French . ... Inserm, led by Claude Gronfier (Inserm Unit 846: Stem ... conducted a study under real conditions on the body ... Concordia. The researchers have shown that a particular kind ... biological rhythms are correctly synchronised despite the absence of ...
Breaking Medicine News(10 mins):Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 4Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4
... 22 ResMed Inc. (NYSE: RMD ), announced ... its results for the third quarter and nine months of ... with ResMed,s results will be issued after 1:00 p.m. Pacific ... webcast to review its results, market trends, and future outlook.The ...
... study finds older people taking NSAIDs more likely to suffer ... suggested that older people who want to avoid Alzheimer,s disease ... ibuprofen and naproxen, but a new study suggests that might ... ,Should I take these to prevent dementia?, the answer ...
... BALTIMORE, April 22 XLHealth, owner and operator of ... Advantage chronic condition Special Needs Plans, supports the proposed ... in the first of a series of round-table discussions ... The hearing,s focus on using the Medicare system as ...
... professional groups join with Congressional sponsors Reps. Israel, Brady ... access to IVIGWASHINGTON, April 22 Members ... introduction of new legislation - H.R. 2002, Medicare Patient ... inadequate Medicare reimbursements that currently restrict patient access to ...
... Study finds no link to condition that can increase ... Soy isoflavones don,t increase breast density, a new study ... increased breast density is associated with a higher risk ... that dietary factors, including isoflavones (estrogen-like plant compounds) might ...
... New York Times best-selling author and mother of five ... special family gathering to celebrate her status as a mom. Instead, ... seeking favors and just plain hard work. Novak,s 5th Annual Online ... May is a labor of love for her son who has ...
Cached Medicine News:Health News:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2009 Results 2Health News:Painkillers May Not Protect Against Dementia 2Health News:Painkillers May Not Protect Against Dementia 3Health News:XLHealth Statement on Senate Finance Committee Roundtable on Healthcare Reform 2Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 2Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 3Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 4Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 2Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 3Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 4
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
(Date:7/30/2014)... and NEW YORK , ... ACCP), a developer of new products for oncology supportive ... MuGard ® , has been featured in an article ... Mucositis Symptoms in Head and Neck Cancers."  Dr. ... provides insight on the growing demand seen in the ...
(Date:7/30/2014)... 2014   Bluegrass Vascular Technologies , a ... devices and methods for vascular access, today announced ... financing, which was led by Targeted Technology ... allow Bluegrass Vascular to obtain CE Mark for ... capabilities, and proceed with US regulatory submissions. The ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Medicine Products: